<DOC>
	<DOC>NCT02052622</DOC>
	<brief_summary>To investigate the long-term safety and maintenance of efficacy of ATX-101 in reduction of submental fat</brief_summary>
	<brief_title>Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101</brief_title>
	<detailed_description>In the study, patients who completed the randomized, double-blind, placebo-controlled phase 3 studies ATX-101-10-16 and ATX-101-10-17 and where recruited at German study sites are followed-up for up to 2 years. No study medication is administered in this study.</detailed_description>
	<criteria>Signed written informed consent before any studyrelated activities are carried out Any subject who successfully completed the final visit (visit 7) of a phase 3 clinical trial, ATX1011016 or ATX1011017 for the reduction of submental fat, i.e. subjects must have at least one study treatment administered and have completed the predecessor study up to visit 7 Willingness to comply with the schedule and procedures of the study Subjects who, since the completion of the prior phase 3 study ATX1011016 or ATX1011017, have had or who are undergoing treatment that may affect the evaluation of the submental area (e.g. but not limited to longterm treatment with systemic corticosteroids, liposuction, surgery or other lipolytic treatment in the submental area, treatment with radio frequency, laser procedures, chemical peels, dermal fillers in the neck or chin area or botulinum toxin injections in the neck or chin area)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>submental fat reduction</keyword>
</DOC>